The thesis
PanicFade v4 is a contrarian mean-reversion strategy built on a simple claim: negative headline shocks tend to be overreacted to, and prices revert toward fundamentals. It buys large caps whose sentiment drops below -0.4 while they are already oversold — RSI14 under 35 and trading below their 20-day moving average — and sizes into the panic rather than waiting for a bottom. Exits trigger on reversion: RSI14 climbing back above 50, or price reclaiming the SMA20. A hard stop fires on fresh lows under continued negativity, treating that case as a genuine fundamental break rather than noise. Crucially, the thesis is grounded in recent sentiment-feedback literature (arXiv:2509.11970, 2025) rather than reverse-engineered from the equity curve.
Recent activity
Over the last two weeks the strategy has stayed busy but light — one or two executions per scheduled run, zero rejections. Trades cluster in a handful of names: CAT, NVDA, BAC and GOOGL. The CAT sequence is instructive. It bought at $621.97 on 3 Nov, exited at $585.79 the next day, re-entered at $561.74, sold at $559.24, then bought again at $597.56. NVDA showed a similar round trip — 8 shares bought at $166.95 on 10 Nov, sold at $164.33 on 12 Nov. These are exactly the whipsaws you expect when fading a falling knife: the stops are doing their job, but at a cost. Portfolio value has hovered in a tight $9,599–$9,746 band, with roughly $5.7k–$7.0k parked in cash — the book is far from fully deployed.
Backtest and validation
On paper the record is strong: +37.93% total return over 1,233 days (a 6.79% CAGR), a 0.96 Sharpe, a 62.88% win rate across 530 trades, and a contained 9.3% max drawdown. More reassuring is the walk-forward validation — four folds, all four positive, with returns improving across time (1.6% → 3.88% → 10.14% → 21.7%) and the most recent out-of-sample fold posting a 2.44 Sharpe. A Probabilistic Sharpe Ratio of 0.985 across 27 trials argues the edge is unlikely to be pure luck.
Strengths and risks
The strengths are real: a theory-first thesis, four-for-four positive folds, a high PSR, and disciplined stops that cap drawdown. The risks are just as clear. Annualized return is a modest 6.79% — the headline 37.93% is cumulative over roughly five years. Turnover is enormous at 5,807%, generating $530 in fees; for single-digit CAGR, cost drag is not a rounding error. The Deflated Sharpe Ratio of 0.56, which penalizes those 27 trials, is far soberer than the raw 0.96 and a healthy reminder that multiple-testing inflation is real. And live results so far are flat-to-slightly-negative, with the CAT and NVDA round trips showing how choppy, trendless tape punishes a dip-buyer.
Verdict
PanicFade v4 is among the better-validated strategies in the stable — the walk-forward evidence is hard to wave away. But its live test is only beginning, and its economics hinge on keeping transaction costs below a thin return margin. Watch turnover and live Sharpe closely before scaling it.